Shanghai Pharma in largest 2011 Hong Kong IPO so far
May 26, 2011 | BY
clpstaff &clp articlesThe H-share listing of Shanghai Pharmaceuticals Holdings (Shanghai Pharma) has raised US$2 billion on the Hong Kong Stock Exchange. At the time of writing,…
The H-share listing of Shanghai Pharmaceuticals Holdings (Shanghai Pharma) has raised US$2 billion on the Hong Kong Stock Exchange. At the time of writing, this stands as the largest initial public offering in Hong Kong this year.
The issuer is a vertically-integrated manufacturer and distributor of pharmaceuticals, and is China's second-largest drug distributor. It has numerous research, manufacturing, distribution and retail outlets.
The joint sponsors of the transaction were Goldman Sachs, China International Capital Corporation, Deutsche Bank and Credit Suisse.
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
Already a subscriber? Log In Now